Aridis Pharmaceuticals, which is developing immunotherapies targeting pathogens associated with pneumonia, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering.
The San Jose, CA-based company was founded in 2003 and booked $1 million in revenue for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol ARDS. Cantor Fitzgerald is the sole bookrunner on the deal. No pricing terms were disclosed.
